Clostridium Difficile Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Clostridium Difficile Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A13281
Year End sale Buy Now

Market Overview:

The 7 major Clostridium difficile infection markets reached a value of US$ 9.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14.9 Billion by 2034, exhibiting a growth rate (CAGR) of 4.7% during 2024-2034.

Report Attribute
Key Statistics
Base Year 
2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Size in 2023
US$ 9.0 Billion
Market Forecast in 2034
US$ 14.9 Billion
Market Growth Rate 2024-2034
4.7%


The Clostridium difficile infection market has been comprehensively analyzed in IMARC's new report titled "Clostridium Difficile Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Clostridium difficile infection (CDI) refers to a bacterial infection caused by the pathogenic bacterium Clostridium difficile, commonly known as C. difficile. This bacterium can colonize the colon and disrupt the normal balance of gut flora, leading to a range of gastrointestinal symptoms. The indications of CDI can vary in severity and may include watery diarrhea, abdominal pain, fever, loss of appetite, and nausea. In severe cases, the ailment can progress to pseudomembranous colitis, a more severe inflammation of the colon, which can result in life-threatening complications. Diagnosing CDI typically involves several steps. The primary method is to test a stool sample for the presence of C. difficile toxins or the bacterium itself. A positive test result, along with clinical symptoms, is often sufficient to confirm the infection. Additionally, healthcare providers may perform a colonoscopy or sigmoidoscopy to visually inspect the colon for signs of inflammation or pseudomembranes.

Clostridium Difficile Infection Market

The increasing utilization of broad-spectrum antibiotics, which can impair the balance of beneficial bacteria in the colon, thereby allowing C. difficile to overgrow and produce toxins that cause infection, is primarily driving the Clostridium difficile infection market. In addition to this, the inflating demand for effective medications, including vancomycin and fidaxomicin, as well as the emerging use of fecal microbiota transplantation (FMT) to restore a healthy gut microbiome, is also creating a positive outlook for the market. Moreover, the widespread adoption of infection control measures and stringent hygiene protocols in healthcare facilities, as they play a vital role in preventing CDI transmission, is further bolstering the market growth. Apart from this, the rising application of rapid diagnostic tests, such as enzyme immunoassays (EIAs) and nucleic acid amplification tests (NAATs), for early and accurate detection of the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of innovative treatment modalities like monoclonal antibodies targeting bacterial toxins, which aid in neutralizing the harmful effects of the bacterium, is also augmenting the market growth. Furthermore, the ongoing research into novel vaccines against C. difficile, aimed at preventing CDI occurrence in high-risk populations is expected to drive the Clostridium difficile infection market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Clostridium difficile infection market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Clostridium difficile infection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Clostridium difficile infection market in any manner.

Recent Developments:

  • In May 2024, Vedanta Biosciences reported that the first patient had been dosed in the global Phase 3 RESTORATiVE303 clinical trial. The RESTORATiVE303 trial is assessing the efficacy and safety of VE303 in patients with recurrent C. difficile infection. It is intended to serve as the foundation for a Biologics License Application (BLA) to be filed with the US Food and Drug Administration.


Key Highlights:

  • Clostridium difficile causes 15-25% of antibiotic-associated diarrhea and almost all cases of antibiotic-associated pseudomembranous colitis.
  • More than 90% of C. difficile infections develop after or during antibiotic treatment.
  • Asymptomatic carriers of C. difficile can contaminate the hospital environment. The frequency of carriers is roughly 3% in healthy persons, 20-30% in hospitalized patients, and 50% in those with lengthy hospital stays.
  • The CDC estimates that C. difficile causes almost half a million illnesses in the United States each year.
  • One out of every eleven patients over the age of 65 who are diagnosed with a healthcare-associated C. diff infection dies within a month.


Drugs:

ZINPLAVA is a human monoclonal antibody that binds to Clostridioides difficile toxin B. It is used to reduce the recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients aged 1 year and older who are receiving antibacterial drug treatment for CDI and are at high risk for recurrence.

VE303 is a potential first-in-class live biotherapeutic product (LBP) candidate composed of specified bacterial consortia intended to prevent recurrent Clostridioides difficile infection. It comprises of eight strains that were rationally chosen utilizing Vedanta's product engine. VE303 is made from pure, clonal bacterial cell banks, resulting in a uniform medicinal product in powdered form and eliminating the need to rely on donor feces of varying composition.

CP101 is an investigational microbiome treatment that delivers a whole microbial community in a single oral delivery, eliminating the requirement for bowel preparation. CP101 is intended to prevent recurrent C. difficile infection by restoring a varied microbial community and important physiological mechanisms that are thought to contribute to colonization resistance.


Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the Clostridium difficile infection market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the Clostridium difficile infection market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs


Competitive Landscape:

This report also provides a detailed analysis of the current Clostridium difficile infection marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Zinplava (bezlotoxumab) Merck & Co
Rebyota (fecal microbiota, live - jslm) Rebiotix
Vowst (fecal microbiota spores, live-brpk) Seres Health
Dificid (Fidaxomicin) Merck
VE303 Vedanta Biosciences
RBX7455 Rebiotix
CP101 Finch Research and Development
MGB BP 3 MGB Biopharma
PF-06425090 Pfizer


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:

Market Insights

  • How has the Clostridium difficile infection market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the Clostridium difficile infection market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the Clostridium difficile infection market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of Clostridium difficile infection across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by gender across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by type across the seven major markets?
  • How many patients are diagnosed (2018-2034) with Clostridium difficile infection across the seven major markets?
  • What is the size of the Clostridium difficile infection patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of Clostridium difficile infection?
  • What will be the growth rate of patients across the seven major markets?
     

Clostridium Difficile Infection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for Clostridium difficile infection drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Clostridium difficile infection market?
  • What are the key regulatory events related to the Clostridium difficile infection market?
  • What is the structure of clinical trial landscape by status related to the Clostridium difficile infection market?
  • What is the structure of clinical trial landscape by phase related to the Clostridium difficile infection market?
  • What is the structure of clinical trial landscape by route of administration related to the Clostridium difficile infection market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Clostridium Difficile Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase Options Year End sale




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARATI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More
DEinternational Egypt

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

Read More
Gulf Excellent Group

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Read More
FS Corporation Inc.

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

Read More
Egyptian Industrial Investment Group

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

Read More
Vishnu Chemicals

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

Read More
MOUNT EVEREST BREWERIES LIMITED

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

Read More
Borges Branded Foods

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

Read More
Godrej Consumer Products Limited

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

Read More
ADC Therapeutics

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

Read More
Ivanti

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

Read More
Asiatic Electrical & Switchgear P. Ltd.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Read More
Denka Co., Ltd.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.

Read More